MaxCyte Unveils Q4 and Full-Year 2024 Financial Results, Sets Expectations for 2025
MaxCyte’s Q4 and Full Year 2024 Financial Results and 2025 Guidance MaxCyte, Inc., a pioneering biotechnology company, recently disclosed its financial results for the fourth quarter and the full year that ended on December 31, 2024. Additionally, the company shared its 2025 guidance. Based on the company’s announcement, the following sections provide a detailed analysis…